photo: ajmc.com
Feb 7, 2026, 15:24
Abeer Alanazi: Asundexian Reduces Stroke and Mortality Without Increased Bleeding
Abeer Alanazi, American Board Certified Pharmacotherapy Specialist and member at European Stroke Organisation (ESO), shared a post on LinkedIn.
“OCEANIC-STROKE
- Patients with non-cardioembolic ischemic stroke or TIA
- Concomitant dual antiplatelet therapy (DAPT)
- Asundexian initiated within 72 hours of symptom onset
- 6,162 patients received asundexian; 6,165 received placebo
- Treatment duration: 3–31 months
- 30% of patients had NIHSS >4
Efficacy
- Significant reduction in acute ischemic stroke (AIS)
- Significant reduction in cardiovascular mortality
- Significant reduction in all-cause mortality
Treatment effects were consistent across the overall population and all prespecified subgroups throughout the treatment period.
Safety
- No increase in major bleeding
- No increase in non-major bleeding
- No increase in symptomatic intracranial hemorrhage (sICH)
- No increase in hemorrhagic stroke
- No increase in fatal bleeding”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics